Literature DB >> 6240470

Experiences on the efficacy and safety of nalidixic acid, oxolinic acid, cinoxacin and norfloxacin in the treatment of urinary tract infections (UTI).

M S Sabbour, M A El Bokl, L M Osman.   

Abstract

The purpose of this study was to determine the effectiveness and tolerability of norfloxacin, cinoxacin and oxolinic acid in the treatment of urinary tract infections (UTI) in comparison to nalidixic acid. 125 patients were given the drugs in the appropriate doses for 10-14 days and 30 patients were treated for six weeks. Clinical, bacteriological, hematological and chemical checks were made on all patients before and after treatment. It was found that norfloxacin, cinoxacin and oxolinic acid are safe and effective against Escherichia coli, Klebsiella and Proteus, the commonly encountered organisms in urinary tract infections. The cure rate for norfloxacin was 93%, for cinoxacin 83%, for oxolinic acid 80% and for nalidixic acid 70% in the short course. However, these differences were not statistically significant. Oxolinic acid, cinoxacin and norfloxacin have the advantage over nalidixic acid of being administered only twice daily.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6240470     DOI: 10.1007/bf01645218

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

Review 1.  Drug therapy reviews: oxolinic acid.

Authors:  R Gleckman; S Alvarez; D W Joubert; S J Matthews
Journal:  Am J Hosp Pharm       Date:  1979-08

2.  Nalidixic acid and oxolinic acid in the treatment of chronic bacteriuria.

Authors:  E Atlas; H Clark; F Silverblatt; M Turck
Journal:  Ann Intern Med       Date:  1969-04       Impact factor: 25.391

3.  Oxolinic acid treatment of urinary-tract infections.

Authors:  D J D'Alessio; V M Olexy; G G Jackson
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1967

4.  Urinary tract infection treated with oxolinic acid.

Authors:  B S Pearson
Journal:  Med J Aust       Date:  1975-02-01       Impact factor: 7.738

5.  Long-term low dose cinoxacin therapy for the prevention of recurrent urinary tract infections.

Authors:  R R Landes
Journal:  J Urol       Date:  1980-01       Impact factor: 7.450

6.  Efficacy of cinoxacin in urinary tract infections.

Authors:  A P Panwalker; H Giamarellou; G G Jackson
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

7.  Pharmacokinetics of nalidixinic acid and oxolinic acid in healthy women.

Authors:  P T Männistö
Journal:  Clin Pharmacol Ther       Date:  1976-01       Impact factor: 6.875

8.  The antibacterial and pharmacological activity of oxolinic acid (Prodoxol).

Authors:  M J Kershaw; D A Leigh
Journal:  J Antimicrob Chemother       Date:  1975-09       Impact factor: 5.790

9.  Pharmacology of cinoxacin in humans.

Authors:  H R Black; K S Israel; R L Wolen; G L Brier; B D Obermeyer; E A Ziege; J D Wolny
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

10.  In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

Authors:  A Ito; K Hirai; M Inoue; H Koga; S Suzue; T Irikura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

  10 in total
  5 in total

1.  The place of quinolones in antibacterial therapy in hospitals.

Authors:  R P Mouton
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

2.  Comparison of norfloxacin versus nalidixic acid in therapy of acute urinary tract infections.

Authors:  L K Selin; G K Harding; M J Thomson; J K Kennedy; B A Urias; A R Ronald
Journal:  Can J Infect Dis       Date:  1990

Review 3.  Quinolones in urology.

Authors:  K T Nielsen; P O Madsen
Journal:  Urol Res       Date:  1989

Review 4.  Microbial transformations of antimicrobial quinolones and related drugs.

Authors:  Igor A Parshikov; John B Sutherland
Journal:  J Ind Microbiol Biotechnol       Date:  2012-09-25       Impact factor: 3.346

5.  New 4-quinolones in the treatment of urinary tract infections.

Authors:  J B Boerema
Journal:  Pharm Weekbl Sci       Date:  1986-02-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.